Second-Line Therapy Options in Metastatic Castration-Resistant Prostate Cancer
Robert Dreicer, MD, discusses the available second-line therapy options and unmet needs in metastatic castration-resistant prostate cancer.
Related Articles
18-gene urine test may reduce unnecessary prostate biopsies
The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of…
Dr. Goudelocke outlines stand-up urgency in patients with OAB
“There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they…
Future work in urology may look at factors influencing pursuit of the field
“We can also look at the timing of exposure to urology. Does early exposure spark interest in urology, or does delayed introduction to the field…
Study launches of CAR T therapy for bone metastatic prostate cancer
“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective…
Expert discusses meta-analysis of prostate radiotherapy
“In my view, at present in patients that have low-volume oligometastatic de novo metastatic prostate cancer, it’s really an unknown whether comprehensive SBRT or other…
UTv Videos
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Study finds disparities in management of mCSPC
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for…
Dr. Marhamati on Aquablation in an ambulatory surgery center
“We are very excited here at Potomac Urology to be the first center in the United States, and just the second center internationally, to offer…
212Pb SPECT/CT imaging shows initial benefit, feasibility in mCRPC
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…
Prostate cancer salvage therapy guideline incorporates PSMA-PET imaging
“A key piece of the guideline is that we need to offer radiation at a PSA of 0.5 ng/mL or lower and maybe even, for…